SCHEMBL1574535

SCHEMBL1574535

Cc1ccc(NC(=O)N2CC(N3CCC4(CC3)OCCO4)C2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 5/20 0.48
TP53 P04637 4/20 0.48
HTT P42858 3/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
GAA P10253 2/20 0.46
HPGD P15428 1/20 0.46
POLB P06746 2/20 0.45
NAMPT P43490 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
SHMT2 P34897 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575247 0.87 KMT2A (0.57) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575447 0.86 SMN1; SMN2 (0.57) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575381 0.85 ALDH1A1 (0.50) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575860 0.85 NPC1 (0.58) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575474 0.83 ALDH1A1 (0.55) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1574852 0.83 TP53 (0.59) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575749 0.83 NPC1 (0.70) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL1575453 0.83 ALDH1A1 (0.56) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575042 0.83 ALDH1A1 (0.58) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1575329 0.82 ALDH1A1 (0.74) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB NPC1 413/4885RAB9A 898/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.